2023
Adjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium
Vieira A, Puthenpura V, Krailo M, Fallahazad N, Brougham M, Murray M, Frazier A, Lopes L, Pashankar F. Adjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium. Pediatric Blood & Cancer 2023, 70: e30426. PMID: 37243320, DOI: 10.1002/pbc.30426.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaOverall survivalImmature teratomaPostoperative chemotherapyBrazilian patientsStage IIAdjuvant chemotherapyUK cohortGrade 1 diseaseGrade 3 patientsReceipt of chemotherapyMainstay of therapyValue of chemotherapyPrimary outcome measureClinical trial dataIT patientsEntire cohortUK patientsRelapse riskBrazilian cohortOutcome measuresPractice variationChemotherapyPatientsStage I
2018
Validation of a new American Association for the Surgery of Trauma (AAST) anatomic severity grading system for acute cholecystitis
Vera K, Pei KY, Schuster KM, Davis KA. Validation of a new American Association for the Surgery of Trauma (AAST) anatomic severity grading system for acute cholecystitis. Journal Of Trauma And Acute Care Surgery 2018, 84: 650-654. PMID: 29271871, DOI: 10.1097/ta.0000000000001762.Peer-Reviewed Original ResearchConceptsLength of stayAcute cholecystitisICU useGrade 2Anatomic gradingAdverse eventsGrade 1Longer LOSAnatomic grading systemGrade 1 diseaseEmergency general surgeryGrade 3 patientsRetrospective cohort studyIncidence of complicationsMajority of patientsTertiary medical centerLow-grade diseaseSurgery of TraumaRisk-adjusted outcomesGood inter-rater reliabilityAAST gradeAmerican AssociationCholecystitis severityCohort studyConsecutive patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply